How can I learn more?

If you have any questions about or interest in any of the above clinical trials, please reach out to our research team at research@corticacare.com.

Click this link to fill out our research interest form.

Current Research Studies

Cortica is currently seeking participants to enroll in ongoing clinical research trials. These trials are open to all families and are not limited to Cortica patients.

1 - Tourette Syndrome Study Emalex Biosciences is evaluating the efficacy of Ecopipam in children, adolescents, and adults with Tourette Syndrome through a phase 3 study at Cortica’s Northern California (Marin) and Los Angeles (Glendale) locations. The study includes 6 months of treatment and an opportunity for a 2-year open-label extension if desired. Someone you know may be eligible to participate if they are at least 6 years old, diagnosed with Tourette Syndrome, and experience both motor and vocal tics. For more information or to see if someone you know may be a good fit for this trial, please reach out to research@corticacare.com

2 - EarliTec MEASURE-ASD Study Earlitec Diagnostics is collaborating with Cortica for a clinical research study to investigate whether an innovative eye-tracking device, called Earlipoint, can be used as a treatment monitoring tool to help detect developmental changes in children with ASD. This trial is taking place at our Northern California (Marin) and several of our Southern California (Glendale, Westlake Village, Torrance) locations. The study includes 7 visits over a 6-month period, where your child will undergo testing by the Earlipoint device as well as evaluation of their developmental status. Your child may be eligible if they are 15 months to 6.5 years old and are either typically developing or have an autism diagnosis and are enrolled in treatment. For more information on Earlitec’s eye-tracking technology, please see https://www.earlitecdx.com/.

3 - The Penguin Study Acadia Pharmaceuticals is evaluating the efficacy of Pimavanserin, an investigational medication, to determine if it may treat irritability and other behaviors in autistic children and adolescents. This trial is taking place at both our Northern California (Marin) and Los Angeles (Glendale) locations. The study includes 6 weeks of treatment and an opportunity for a year-long open label extension if desired. Your child may be eligible if they are 5-17 years old, diagnosed with autism, experience high levels of irritability, and have limited exposure to antipsychotic medications. For more information or to see if someone you know may be a good fit for this trial, please see www.penguinautismstudy.com.

Cortica Researchers

The Cortica Innovation Network is led by Dr. Elysa Marco, Dr. Kevin Shapiro, and Dr. Suzanne Goh. Serving as leads in their respective fields, they come together to bridge Cortica researchers and cross-functionally collaborate on groundbreaking research.

Interested in learning more about our model and the research behind it? Read more below.